Medical Developments International Limited · ASX:MVP
Medical Developments International — Non-Deal Roadshow (October 2016)
43 slides from Medical Developments International's roadshow presentation, Oct 24, 2016
Slide 1: Medical Developments International Asian Road Show
For personal use only Medical Developments International Asian Road Show
Slide 2: Disclaimer
Disclaimer This presentation contains certain forward-looking statements. These forward-looking statements may be identified by words such as ‘believes’, ‘expects’, ‘anticipates’, ‘projects’, ‘intends’, ‘should’, ‘seeks’, ‘estimates’, ‘future’ or similar expressions or by discussion of, among other
Slide 3: Vision
Vision For personal use only Medical Developments International (MDI) is a leading Emergency Medicine Company. Our aim is to: 1. Provide unique and innovative products to assist our customers in the management of acute pain, trauma and procedural pain and to be the market leader in these markets glo
Slide 4: The Business
The Business For personal use only MDI is delivering two world class “company making” business opportunities. The risk profile of these opportunities is relatively low and well understood. Penthrox: Penthrox has the potential to be the market leader in analgesic markets around the world. Penthrox is
Slide 5: Introducing Penthrox
For personal use only Introducing Penthrox
Slide 6: A world class opportunity: Penthrox
Penthrox A world class opportunity For personal use only Penthrox® • Market Leader for trauma pain • Opiate sparing, fast acting inhalational analgesic 1 • 85% of patients reach clinical analgesia within 10 breaths • Is a solution to a significant unmet clinical need • Demonstrated safety and effica
Slide 7: A world class opportunity: Penthrox
Penthrox A world class opportunity For personal use only Penthrox® • Sold in 15 countries around the world including Australia, UK, France Ireland , South Africa, Singapore, Belgium, New Zealand, UAE, Qatar and elsewhere • Major distribution deals signed in Europe and elsewhere in 2015. • $15 millio
Slide 8: Clinical application
Penthrox Clinical application For personal use only Painful procedures Painful procedures Cosmetic Dentistry Surgery • Cutaneous excisions • Burn injuries • Liquid nitrogen • Breaks, Military Consulting removals of skin- fractures and Rooms cancers, warts, etc. dislocations • Invasive • Abdomen pain
Slide 9: Benefits to medical professionals
Penthrox Benefits to medical professionals For personal use only Rapid onset of Minimal waiting time before a painful procedure can be performed (3 minutes) and rapid pain relief when a patient is treated for acute pain, action trauma, and minor surgical procedures. Inhaled self- Medical professiona
Slide 10: Benefits over Opiates
Penthrox Benefits over Opiates For personal use only The benefits of using Penthrox® over Morphine include: • Penthrox does not effect vital signs; no clinical depression of respiration or circulation. • Penthrox can be used on children, Morphine often cannot. • Penthrox is not a narcotic, nor is it
Slide 11: Benefits over Nitrous Oxide
Penthrox Benefits over Nitrous Oxide For personal use only The benefits of using Penthrox® over Nitrous Oxide include: • Penthrox does not effect vital signs; no clinical depression of respiration or circulation. • Penthrox is self-administered and easy to use. • Penthrox is compact and can be used
Slide 12: Non-narcotic and clinically proven efficacy
Penthrox Non- narcotic and clinically proven efficacy For personal use only VAS scores compared, IV morphine vs IN fentanyl vs Penthrox Summary of mean VAS Pain Scores The criteria for the cross study comparison were a similar study design and endpoint as the Penthrox® Time 0 5 minutes 10 minutes 15
Slide 13: Value proposition
Penthrox value proposition For personal use only Penthrox can materially improve the Non-narcotic trauma relief, throughput of patients7,8 in the ER. It enables non-addictive, safe.1 better time to analgesia and less medical care and observation compared with opioids. Not a restricted medicine Penth
Slide 14: Potential global sales for Acute Trauma pain $2 billion+
Penthrox Potential global sales for Acute Trauma pain $2 billion+ For personal use only Peak sales in UK estimated to Peak sales in Canada could be be $72 million per annum* $50 million per annum* Peak sales in Europe estimated to be $250 million per annum* Peak sales in Asia could be $500 million p
Slide 15: USA
Penthrox USA For personal use only MVP submitted a detailed regulatory package to the FDA in January 2016. We received a written response from the FDA detailing it’s opinion on the strengths of our regulatory package and by inference the work required to get Penthrox approved for sale in the United
Slide 16: Clinical development program
Penthrox Clinical development program For personal use only Additional clinical trials and studies are planned for FY17 (and beyond) which will broaden the indications for use of Penthrox® including: We are developing a program of work to support additional indications for Penthrox worldwide. Our lo
Slide 17: Clinical development program: Minor Surgical Procedures
Penthrox Clinical development program For personal use only Minor Surgical Procedures Penthrox is already approved for use in Minor Surgical Procedures in Australia and elsewhere. MVP is working with its partners to develop a clinical program to extend the indication of use in markets around the wor
Slide 18: Potential global sales for Minor Surgical Procedures $2.3 billion+
Penthrox Potential global sales for Minor Surgical Procedures $2.3 billion+ For personal use only Peak sales in USA could be $1.3billion per annum* Peak sales in Europe estimated to be $814 million per annum* Peak sales in Asia could be $147 million per annum* Peak sales in Latin America estimated t
Slide 19: Clinical development program: Breakthrough Pain / Repeat Use
Penthrox Clinical development program For personal use only Breakthrough Pain / Repeat Use MVP has begun the clinical program to get Penthrox approved for sale in the USA. As part of that program, several pre-clinical trials will be concluded. These trials will also be used towards the work program
Slide 20: Potential global sales for Breakthrough pain $6 billion+
Penthrox Potential global sales for Breakthrough pain $6 billion+ For personal use only Peak sales in USA could be $2 billion per annum* Peak sales in Europe could be $2 billion per annum* Peak sales in Asia could be $1.5 billion per annum* Peak sales in Latin America could be $500 million per Peak
Slide 21: Clinical development program: Home Use
Penthrox Clinical development program For personal use only Home Use Ultimately, we hope the clinical programs we undertake will allow Penthrox to be approved for home use via prescription. Our visions is that households all over the world will have a Penthrox device for use during those rare occasi
Slide 22: Potential global sales for Home Use $3 billion+
Penthrox Potential global sales for Home Use $3 billion+ For personal use only Peak sales in USA could be $900 million per annum* Peak sales in Europe could be $1 billion per annum* Peak sales in Asia could be $620 million per annum* Peak sales in Latin America estimated to be $230 million Peak sale
Slide 23: New Markets and Regulatory Submissions in FY17 and beyond
Penthrox For personal use only New Markets and Regulatory Submissions in FY17 and beyond Rest of Europe Canada Belgium Russia France Saudi Arabia USA Jordon Iraq Korea Taiwan Iran Mexico Latin America
Slide 24: Intellectual Property
Penthrox Intellectual Property For personal use only MDI is protecting its future by generating intellectual property from its manufacturing technology and delivery devices. In the last 12 months MDI has filed and is managing the following patents and trademarks: • 4 Penthrox Inhaler patents; • 1 ma
Slide 25: Manufacturing
Penthrox Manufacturing For personal use only MDI has invested millions of dollars developing new manufacturing technology, techniques and methods. MDI has: 1. Intellectual property. 2. Global production capacity. 3. Lowest cost to manufacture. 4. Significant competitive advantage.
Slide 26: Outlook
Penthrox Outlook For personal use only MVP’s ambition is to globalise Penthrox and in doing so make it the main stream analgesic of choice around the world. That process has begun. Over the next 12 months we expect to: 1. Obtain approval to sell Penthrox in more than 20 countries throughout Europe a
Slide 27: Introducing Respiratory Devices
For personal use only Introducing Respiratory Devices
Slide 28: MDI Medical Respiratory division
MDI Medical Respiratory division For personal use only MDI has a long history of investing R&D resources to design and improve respiratory devices used to deliver Asthma and COPD medication. In 2011 MDI launched a new range of products using MDI’s Cross Valve TechnologyTM, a patented system of drug
Slide 29: MDI Medical Respiratory division
MDI Medical Respiratory division For personal use only MDI offers a range of devices that can be used to help patients manage and take control of their asthma and COPD. • Space Chamber PlusTM anti-static range • Space Chamber PlusTM aerosol spacer • Space ChamberTM re-usable • Compact Spacer Chamber
Slide 30: MDI Medical Respiratory division
MDI Medical Respiratory division For personal use only Recently approved by the FDA for sale in the USA. Recently approved for full reimbursement in the UK. New distribution partners in the USA, Portugal, Spain and first sales. Growing business internationally.
Slide 31: Respiratory Devices: Existing distribution network
Respiratory Devices Existing distribution network For personal use only Netherlands Switzerland Austria Germany UK Belgium Canada Greece Italy USA Spain Korea Portugal Singapore Malaysia Hong Kong UAE New Zealand Australia
Slide 32: Respiratory division Future
Respiratory division Future For personal use only MDI is investing heavily in developing new and innovative products • Anti static spacers • Anti static mask – (1st of its kind) • Collapsible spacer • Additional patentable devices and technology
Slide 33: Respiratory Devices Intellectual Property
Respiratory Devices Intellectual Property For personal use only MDI is protecting its future by generating intellectual property from its new range of respiratory devices. MDI has filed a number of global patents. MDI has filed more than 20 international Trade Marks and Registered Designs.
Slide 34: Respiratory Devices Outlook
Respiratory Devices Outlook For personal use only MVP’s ambition is to globalise the sales of its Respiratory Devices. That process has begun. We already have partners and make sales in more than 18 countries. Over the next 12 months we expect to: 1. Obtain additional partnership deals in the USA an
Slide 35: Introducing MVP corporate
For personal use only Introducing MVP corporate
Slide 36: Financial summary of FY16
Financial summary of FY16 For personal use only
Slide 37: Financial summary of FY16: Penthrox
Financial summary of FY16 Penthrox For personal use only ….. Other key highlights • Australian hospitals grew 30% • Australian ambulance business continues to grow • Middle East sales growth of 31%
Slide 38: Financial summary of FY16: Respiratory
Financial summary of FY16 Respiratory For personal use only Other key highlights • Strong result given New Zealand government contract was not renewed • Sales into Asia grew by more than 70% • New distribution partners in the USA
Slide 39: Financial Summary
Financial Summary For personal use only MDI has been profitable every year since listing on the ASX in 2003 and used those profits for registration and additional clinical studies and: • has generated a positive cash flow every year; • pays tax and has paid fully franked dividends; • has received al
Slide 40: MDI Investor Dashboard
MDI Investor Dashboard (ASX: MVP) For personal use only Historical Stock Chart (3yr) Current stock Price 5.290 ▲0.010 (0.19%) 19 Oct, 2:10pm Day High 5.310 Day Low 5.230 Open 5.280 Prev. Close 5.300 Volume 21,084 52 Wk. High 6.850 (3 May 2016) 52 Wk. Low 2.850 (18 Jan 2016) Mkt. Cap 309.06 (Mil)
Slide 41: MDI Corporate Overview
MDI Corporate Overview David Williams Dr Harry Oxer Leon Hoare Max Johnston Allan McCallum Phillip Powell For personal use only Non-Executive Non-Executive Non-Executive Non-Executive Non-Executive Non-Executive Chairman Director Director Director Director Director The Managing A Medical Consultant
Slide 42: MDI Global strategy
MDI Global strategy New and revised For personal use only materials and process (lowest cost producer and significant IP) New Business Partners Product innovation (worlds best delivery devices and significant IP) Clinical trials (Commercial clinical studies to support marketing and Regulatory produc
Slide 43: Contact details
Contact details For personal use only HEAD OFFICE 4 Caribbean Drive Scoresby, Victoria, Australia, 3179 Tel: +61 3 9547 1888 Fax: +61 3 9547 0262 Web: www.medicaldev.com
Medical Developments International — Non-Deal Roadshow (October 2016) on 6ix